Preventive healthcare has long promised more than it delivered, but Neko Health's arrival in the US market with its AI-powered body scanning finally gives that promise some real engineering behind it. The company, backed by investor Farooq Abbasi, is bringing a model that turns a routine physical into a data-rich, proactive assessment, something that should make anyone who has waited months for a specialist appointment sit up and pay attention. This is not a gadget for the quantified-self crowd; it is a serious attempt to shift medicine from reactive treatment to early detection, and that distinction matters for every patient who has ever been told "come back when it hurts."
The practical implications are straightforward. Neko's scans use a combination of sensors and machine learning to measure hundreds of physiological markers in about an hour, producing a baseline that can catch anomalies long before symptoms appear. For employers and insurers, that means lower long-term costs and fewer catastrophic claims. For individuals, it means actionable data instead of vague reassurance. Of course, the US healthcare system is not built for this model, it rewards procedures, not prevention, so the real test will be whether Neko can navigate reimbursement and physician adoption without getting ground down by inertia. That challenge is familiar to anyone watching Epic hits pause on new features to prioritize fixing patient data security gaps, where even a dominant health IT giant has to slow its roadmap to address foundational trust issues. Neko will need the same discipline if it wants its data to be trusted, not just collected.
What makes this expansion noteworthy is not the technology alone, body scanning has existed in various forms, but the business logic behind it. Abbasi's investment signals that venture capital sees preventive AI as a viable category, not a moonshot. That is a shift worth watching alongside the broader push to embed intelligence into existing infrastructure, a theme Blackstone's Jas Khaira will explore on the Builders Stage at TechCrunch Disrupt 2026. The question Neko has not yet answered is how it scales beyond early adopters. A scan that requires a dedicated facility and a technician is not the same as a smartphone app, and the company will have to prove that its model can drop into a primary care setting without ballooning costs.
One concrete detail to track: Neko's pricing and insurance coverage in the US market. In Europe, the model relies on out-of-pocket payments and corporate wellness programs. If the company can negotiate direct contracts with self-insured employers or large health plans here, it will validate that preventive scanning is more than a luxury service. If it cannot, the US launch risks becoming a pilot for the wealthy rather than a genuine transformation of preventive care. That distinction will determine whether Neko is a footnote or a foundation.